Clinical trial NCT00454298: Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Regimen, Parallel-Group Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGG-523 Administered Orally to Subjects With Severe Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Osteoarthritis
Keywords: Severe Osteoarthritis
Arthritis
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2007-03-30
Enrollment: 2
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of the study is to find out if, after 4 weeks of dosing, signs of the investigational drug AGG-523, or its effects, can be measured in urine, blood, or the knee joint. A secondary purpose is to evaluate the safety of taking the drug either once a day or twice a day for 4 weeks.

Detailed description: This is a multicenter study of 2 dosing regimens of AGG-523, an investigational aggrecanase inhibitor that is taken orally. Potential study subjects are those with severe Osteoarthritis (OA) of the knee who are scheduled to undergo total joint replacement surgery.

Study subjects will be randomly assigned to 1 of 2 dosing regimens (once-daily or twice-daily dosing) of either 1800 mg AGG-523 or placebo, which will be taken during the 4-week period before having the total knee replacement. The treatments will be assigned using a 4:1 ratio of active to placebo treatment, which means that more subjects will receive the active treatment than the placebo (see below).

* AGG-523 1800 mg once a day (32 subjects)
* AGG-523 900 mg twice a day (32 subjects)
* Placebo once a day (8 subjects)
* Placebo twice a day (8 subjects)

Study subjects will have weekly evaluations as outpatients during the 4-week dosing period. The purpose of these evaluations is to monitor for potential complications, ensure compliance with taking the study drug, ask about the use of other medications, and, when necessary, replenish the supply of study drug. These assessments may be conducted by telephone, as a home visit, or by having the subject travel to the clinic for an outpatient office visit. A final (in person) visit will happen 2 weeks after having total knee replacement surgery.

Eligibility criteria: Inclusion Criteria:

* Generally healthy, men or women, at least 55 years old
* Osteoarthritis of the knee requiring total knee replacement surgery

Exclusion Criteria:

* Other types of arthritis, like rheumatoid arthritis
* Recent major surgery (in past 3 months)
* Recent knee injections (in past 6 months)

Primary outcomes:
measure: Using parts of the knee joint and the surrounding fluid that is taken out at the time of knee replacement, measure 1) the activity of aggrecansase (an enzyme that breaks down cartilage) and 2) the amount of study drug using lab tests.
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
state: Massachusetts
city: Boston
country: United States
state: Massachusetts
city: Newton
country: United States
state: Massachusetts
city: Winchester
country: United States
state: Massachusetts
city: Worcester
country: United States
state: Massachusetts
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Montior
role: STUDY_DIRECTOR
References: